Mechanisms of taxotere-related drug resistance in pancreatic carcinoma

Journal of Surgical Research

Volumn 99, Issue 2, 2001, Pages 179-186

  Liu, Bin ^a   Staren, Edgar D ^a   Iwamura, Takeshi ^b   Appert, Hubert E ^a   Howard, John M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Lung resistance protein; Multidrug resistance; Multidrug resistance protein; P glycoprotein; Pancreatic neoplasm; Taxotere; Tubulin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA TUBULIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; INDOMETACIN; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034895161     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2001.6126     Document Type: Article

References (41)

1. Multimodality treatment of locally advanced pancreatic cancer
2. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs
3. Experimental antitumor activity of Taxotere (RP56976, NSC 628503), a Taxol analogue
4. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro
5. Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group
6. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer
7. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer
8. Phase II study of docetaxel in patients with metastatic pancreatic cancer: A Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan
9. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma
10. Acquisition of Taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells
11. Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel
12. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833
13. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol)
14. Isolation of a Taxol-resistant Leishmania donovani promastigote mutant that exhibits a multidrug-resistant phenotype
15. Microtubule dynamics in vitro are regulated by the tubulin isotype composition
16. Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro
17. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells
18. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
19. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein
20. Relationship between paclitaxel activity and pathobiology of human solid tumors
21. The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines
22. Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: Relevance to indicator of better prognosis
23. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9
24. Heterogeneities of attachment, chemotaxis, and protease production among clones with different metastatic potentials from a human pancreatic cancer cell line
25. Optimization of the tetrazolium-based colorimetric assay for the measurement of cell number and cytotoxicity
26. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
27. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance
28. Non-P-glycoprotein drug export mechanisms of multidrug resistance
29. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells
30. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein
31. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
32. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to Taxol and doxorubicin
33. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein
34. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
35. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
36. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
37. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs
38. Taxol binds to polymerized tubulin in vitro
39. Characterization of the Taxol binding site on the microtubule. 2-(m-Azidobenzoyl)Taxol photolabels a peptide (amino acids 217-231) of beta-tubulin
40. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol
41. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of Taxol resistance